Nephron lover | #NephEdC #NephJC #ISNSoMe team #ISNWCN #SLANHJoven
#nefroneando avanzamos #butfirstcoffee ☕
Life traveler 🧳 🇭🇳🇲🇽🏳️🌈 🇬🇹🇸🇻🇺🇸🇪🇸🏴🇵🇹🇹🇷🇹🇭🇦🇷🇮🇹🇻🇦🇫🇷💥
Loading...
10/10
Final thoughts:
✈️🚉🚗 we made it to #ERA26, sorry we're a little late on the posts! @nephroseeker.medsky.social
Renal biopsy in diabetics is still a gold standard to rule out NDKD and improve the survival in diabetic patients…
Up next, LBCT from #ERA26
Join us at nephjc.com
#TenPostNephJC
#NephSky #NephJC
1/10
How often do we miss non-diabetic kidney disease (NDKD)?
🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash
@glombandit.bsky.social
kidney-international.org/article/S008...
✨Exciting news #NephtSky
The new #NephJC editorial interns are here!
📢Give them a follow and make them feel at home
👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇
www.nephjc.com/news/2025/6/...
Hypertension control remains stubbornly low in underserved communities. IMPACTS‑BP asks whether a team‑based, multi‑component approach can meaningfully improve BP control and adherence in low‑income patients
🎨 #VisualAbstract by @nephromommy-akshu.bsky.social
www.nephjc.com/news/2026/5/...
10/10
Final thoughts
New drug, more data= good. Keep an eye out for data manipulation & always be a little skeptical.
➡️Up next May 19, 2026: Multifaceted Strategies for Hypertension Control in Low-Income Patients (Mills et al, NEJM, 2026)
Join us www.nephjc.com/
How we doing?
9/10
I want more info:
Blog by @sayalibthakare.bsky.social @drsaivani.bsky.social
www.nephjc.com/news/trcpc6inhibition-fsgs
VA by Dr. Divya Bajpai
www.nephjc.com/news/2026/5/3/trpc6-inhibition-the-visual-abstract
8/10
#NephJC
Consensus
1️⃣BI 764198 administration in 1° FSGS caused a modest ⬇️UPCR
2️⃣Unclear if this will lead to better eGFR outcomes in a heterogenous group of FSGS pts
3️⃣Appears most helpful in genetic FSGS with TRPC6 mutations
7/10
Questions 2
#NephJC #Nephsky
There was a lot of statistical manipulation and commentary on subgroups…
Does this concern you in a small phase 2 trial?
Are you aware of the concerns about data manipulation with Avacopan in phase 3 trials?
5/10
A figure paints🖼️ a 1000 words!
This figure is… a lot. Full analysis & per protocol sets at various doses
Small # in each group
A) 1° endpoint: 25% ⬇️ UPCR from baseline
D) Proportion achieving a UPCR of <1 g/g
E) Δ in 24 h UPCR in pts with confirmed TRPC6
4/10
One post results
Of the 60 pts:
1° endpoint (≥ 25% ⬇️ in UPCR from baseline at week 12) was seen in 7% of placebo vs 35% of all BI 764198 dose groups
OR 4.9 [95% CI 1.0–48.8]
Introducing NephJC’s brand new editorial internship class of 2026-2027
For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR...
